Liver Disease Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Liver Disease Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028


The global liver disease treatment market size reached US$ 22.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 33.0 Billion by 2028, exhibiting a growth rate (CAGR) of 6.43% during 2023-2028.

The liver is a vital organ of the human body that performs significant functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining an adequate balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.

Liver Disease Treatment Market Trends:
The rising geriatric population, which is suspetible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the market. The changing dietary patterns and sedentary lifestyles are boosting the market growth. Additionally, the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is favoring the market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the market growth. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. In line with this, the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare industry, and the implementation of various government initiatives to promote public health are creating a positive outlook for the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global liver disease treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on treatment type, disease type and end user.

Breakup by Treatment Type:

Antiviral Drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy

Breakup by Disease Type:

Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others

Breakup by End User:

Hospitals
Ambulatory Surgical Centers
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Viatris Inc.

Key Questions Answered in This Report

1. What was the size of the global liver disease treatment market in 2022?
2. What is the expected growth rate of the global liver disease treatment market during 2023-2028?
3. What are the key factors driving the global liver disease treatment market?
4. What has been the impact of COVID-19 on the global liver disease treatment market?
5. What is the breakup of the global liver disease treatment market based on the treatment type?
6. What is the breakup of the global liver disease treatment market based on the disease type?
7. What is the breakup of the global liver disease treatment market based on the end user?
8. What are the key regions in the global liver disease treatment market?
9. Who are the key players/companies in the global liver disease treatment market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Liver Disease Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Treatment Type
6.1 Antiviral Drugs
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Immunosuppressants
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Vaccines
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Immunoglobulins
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Corticosteroids
6.5.1 Market Trends
6.5.2 Market Forecast
6.6 Targeted Therapy
6.6.1 Market Trends
6.6.2 Market Forecast
6.7 Chemotherapy
6.7.1 Market Trends
6.7.2 Market Forecast
7 Market Breakup by Disease Type
7.1 Hepatitis
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Autoimmune Diseases
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Non-alcoholic Fatty Liver Disease (NAFLD)
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Cancer
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Genetic Disorders
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Ambulatory Surgical Centers
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
 9.1.1.1 Market Trends
 9.1.1.2 Market Forecast
9.1.2 Canada
 9.1.2.1 Market Trends
 9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
 9.2.1.1 Market Trends
 9.2.1.2 Market Forecast
9.2.2 Japan
 9.2.2.1 Market Trends
 9.2.2.2 Market Forecast
9.2.3 India
 9.2.3.1 Market Trends
 9.2.3.2 Market Forecast
9.2.4 South Korea
 9.2.4.1 Market Trends
 9.2.4.2 Market Forecast
9.2.5 Australia
 9.2.5.1 Market Trends
 9.2.5.2 Market Forecast
9.2.6 Indonesia
 9.2.6.1 Market Trends
 9.2.6.2 Market Forecast
9.2.7 Others
 9.2.7.1 Market Trends
 9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
 9.3.1.1 Market Trends
 9.3.1.2 Market Forecast
9.3.2 France
 9.3.2.1 Market Trends
 9.3.2.2 Market Forecast
9.3.3 United Kingdom
 9.3.3.1 Market Trends
 9.3.3.2 Market Forecast
9.3.4 Italy
 9.3.4.1 Market Trends
 9.3.4.2 Market Forecast
9.3.5 Spain
 9.3.5.1 Market Trends
 9.3.5.2 Market Forecast
9.3.6 Russia
 9.3.6.1 Market Trends
 9.3.6.2 Market Forecast
9.3.7 Others
 9.3.7.1 Market Trends
 9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
 9.4.1.1 Market Trends
 9.4.1.2 Market Forecast
9.4.2 Mexico
 9.4.2.1 Market Trends
 9.4.2.2 Market Forecast
9.4.3 Others
 9.4.3.1 Market Trends
 9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10  SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11  Value Chain Analysis
12  Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13  Price Analysis
14  Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
 14.3.1.1 Company Overview
 14.3.1.2 Product Portfolio
 14.3.1.3 Financials
 14.3.1.4 SWOT Analysis
14.3.2 AbbVie Inc.
 14.3.2.1 Company Overview
 14.3.2.2 Product Portfolio
 14.3.2.3 Financials
 14.3.2.4 SWOT Analysis
14.3.3 Astellas Pharma Inc.
 14.3.3.1 Company Overview
 14.3.3.2 Product Portfolio
 14.3.3.3 Financials
 14.3.3.4 SWOT Analysis
14.3.4 Bristol-Myers Squibb Company
 14.3.4.1 Company Overview
 14.3.4.2 Product Portfolio
 14.3.4.3 Financials
 14.3.4.4 SWOT Analysis
14.3.5 Eli Lilly and Company
 14.3.5.1 Company Overview
 14.3.5.2 Product Portfolio
 14.3.5.3 Financials
 14.3.5.4 SWOT Analysis
14.3.6 Emergent BioSolutions Inc.
 14.3.6.1 Company Overview
 14.3.6.2 Product Portfolio
 14.3.6.3 Financials
 14.3.6.4 SWOT Analysis
14.3.7 F. Hoffmann-La Roche AG
 14.3.7.1 Company Overview
 14.3.7.2 Product Portfolio
 14.3.7.3 Financials
14.3.8 Gilead Sciences Inc.
 14.3.8.1 Company Overview
 14.3.8.2 Product Portfolio
 14.3.8.3 Financials
 14.3.8.4 SWOT Analysis
14.3.9 GlaxoSmithKline plc
 14.3.9.1 Company Overview
 14.3.9.2 Product Portfolio
 14.3.9.3 Financials
 14.3.9.4 SWOT Analysis
14.3.10 Merck & Co. Inc.
 14.3.10.1 Company Overview
 14.3.10.2 Product Portfolio
 14.3.10.3 Financials
 14.3.10.4 SWOT Analysis
14.3.11 Novartis AG
 14.3.11.1 Company Overview
 14.3.11.2 Product Portfolio
 14.3.11.3 Financials
 14.3.11.4 SWOT Analysis
14.3.12 Pfizer Inc.
 14.3.12.1 Company Overview
 14.3.12.2 Product Portfolio
 14.3.12.3 Financials
 14.3.12.4 SWOT Analysis
14.3.13 Sanofi S.A.
 14.3.13.1 Company Overview
 14.3.13.2 Product Portfolio
 14.3.13.3 Financials
 14.3.13.4 SWOT Analysis
14.3.14 Takeda Pharmaceutical Company Limited
 14.3.14.1 Company Overview
 14.3.14.2 Product Portfolio
 14.3.14.3 Financials
 14.3.14.4 SWOT Analysis
14.3.15 Viatris Inc.
 14.3.15.1 Company Overview
 14.3.15.2 Product Portfolio
 14.3.15.3 Financials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings